SeaStar Medical Holding Corp (ICUCW) stock
ICUCWNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as ICU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 3/309% above fair value
$0.01−0.01 (-34.73%)
Close on Oct 30, 2026Market cap $9.87MP/E –Yield –
SeaStar Medical r&d expenses
Research and development expenses are spending on new products and technology.
SeaStar Medical's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.91M, up 4.4% year over year. For fiscal 2025 it was $7.52M, down 17.4% from the year before. The highest annual figure on record is $9.11M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.52M | -17.4% |
| FY2024 | Dec 31, 2024 | $9.11M | +52.4% |
| FY2023 | Dec 31, 2023 | $5.97M | +138.6% |
| FY2022 | Dec 31, 2022 | $2.50M | -9.5% |
| FY2021 | Dec 31, 2021 | $2.77M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.52M | +143.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.34M | -3.6% |
| Q4 FY2025 | Dec 31, 2025 | $2.20M | -19.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.85M | -20.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.04M | -55.6% |
| Q1 FY2025 | Mar 31, 2025 | $2.43M | +43.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.74M | +133.0% |
| Q3 FY2024 | Sep 30, 2024 | $2.34M | +114.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.33M | +17.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.70M | -1.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.18M | +42.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.09M | +49.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.98M | +232.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.73M | +387.3% |
| Q4 FY2022 | Dec 31, 2022 | $825.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $727.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $596.00K | – |
| Q1 FY2022 | Mar 31, 2022 | $355.00K | – |